Treatment of peripheral precocious puberty

Melissa Schoelwer, Erica Eugster

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

There are many etiologies of peripheral precocious puberty (PPP) with diverse manifestations resulting from exposure to androgens, estrogens, or both. The clinical presentation depends on the underlying process and may be acute or gradual. The primary goals of therapy are to halt pubertal development and restore sex steroids to prepubertal values. Attenuation of linear growth velocity and rate of skeletal maturation in order to maximize height potential are additional considerations for many patients. McCune-Albright syndrome (MAS) and familial male-limited precocious puberty (FMPP) represent rare causes of PPP that arise from activating mutations in GNAS1 and the LH receptor gene, respectively. Several different therapeutic approaches have been investigated for both conditions with variable success. Experience to date suggests that the ideal therapy for precocious puberty secondary to MAS in girls remains elusive. In contrast, while the number of treated patients remains small, several successful therapeutic options for FMPP are available.

Original languageEnglish (US)
Pages (from-to)230-239
Number of pages10
JournalEndocrine Development
Volume29
DOIs
StatePublished - 2016

Fingerprint

Precocious Puberty
Polyostotic Fibrous Dysplasia
LH Receptors
Sexual Development
Therapeutics
Androgens
Estrogens
Steroids
Mutation
Growth
Genes
Familial Testotoxicosis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health
  • Endocrinology
  • Endocrine and Autonomic Systems

Cite this

Treatment of peripheral precocious puberty. / Schoelwer, Melissa; Eugster, Erica.

In: Endocrine Development, Vol. 29, 2016, p. 230-239.

Research output: Contribution to journalArticle

Schoelwer, Melissa ; Eugster, Erica. / Treatment of peripheral precocious puberty. In: Endocrine Development. 2016 ; Vol. 29. pp. 230-239.
@article{c88145d59d4f420f80befe18973e87dc,
title = "Treatment of peripheral precocious puberty",
abstract = "There are many etiologies of peripheral precocious puberty (PPP) with diverse manifestations resulting from exposure to androgens, estrogens, or both. The clinical presentation depends on the underlying process and may be acute or gradual. The primary goals of therapy are to halt pubertal development and restore sex steroids to prepubertal values. Attenuation of linear growth velocity and rate of skeletal maturation in order to maximize height potential are additional considerations for many patients. McCune-Albright syndrome (MAS) and familial male-limited precocious puberty (FMPP) represent rare causes of PPP that arise from activating mutations in GNAS1 and the LH receptor gene, respectively. Several different therapeutic approaches have been investigated for both conditions with variable success. Experience to date suggests that the ideal therapy for precocious puberty secondary to MAS in girls remains elusive. In contrast, while the number of treated patients remains small, several successful therapeutic options for FMPP are available.",
author = "Melissa Schoelwer and Erica Eugster",
year = "2016",
doi = "10.1159/000438895",
language = "English (US)",
volume = "29",
pages = "230--239",
journal = "Endocrine Development",
issn = "1421-7082",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Treatment of peripheral precocious puberty

AU - Schoelwer, Melissa

AU - Eugster, Erica

PY - 2016

Y1 - 2016

N2 - There are many etiologies of peripheral precocious puberty (PPP) with diverse manifestations resulting from exposure to androgens, estrogens, or both. The clinical presentation depends on the underlying process and may be acute or gradual. The primary goals of therapy are to halt pubertal development and restore sex steroids to prepubertal values. Attenuation of linear growth velocity and rate of skeletal maturation in order to maximize height potential are additional considerations for many patients. McCune-Albright syndrome (MAS) and familial male-limited precocious puberty (FMPP) represent rare causes of PPP that arise from activating mutations in GNAS1 and the LH receptor gene, respectively. Several different therapeutic approaches have been investigated for both conditions with variable success. Experience to date suggests that the ideal therapy for precocious puberty secondary to MAS in girls remains elusive. In contrast, while the number of treated patients remains small, several successful therapeutic options for FMPP are available.

AB - There are many etiologies of peripheral precocious puberty (PPP) with diverse manifestations resulting from exposure to androgens, estrogens, or both. The clinical presentation depends on the underlying process and may be acute or gradual. The primary goals of therapy are to halt pubertal development and restore sex steroids to prepubertal values. Attenuation of linear growth velocity and rate of skeletal maturation in order to maximize height potential are additional considerations for many patients. McCune-Albright syndrome (MAS) and familial male-limited precocious puberty (FMPP) represent rare causes of PPP that arise from activating mutations in GNAS1 and the LH receptor gene, respectively. Several different therapeutic approaches have been investigated for both conditions with variable success. Experience to date suggests that the ideal therapy for precocious puberty secondary to MAS in girls remains elusive. In contrast, while the number of treated patients remains small, several successful therapeutic options for FMPP are available.

UR - http://www.scopus.com/inward/record.url?scp=84951085860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951085860&partnerID=8YFLogxK

U2 - 10.1159/000438895

DO - 10.1159/000438895

M3 - Article

C2 - 26680582

AN - SCOPUS:84951085860

VL - 29

SP - 230

EP - 239

JO - Endocrine Development

JF - Endocrine Development

SN - 1421-7082

ER -